.04% Atropine Better than .01% or Ortho-K in Managing Myopia
A Chinese clinical trial compared low-dose (0.01%) and mid-dose (0.04%) atropine eye drops with orthokeratology (ortho-K) to manage myopia in children. Over two years, 0.04% atropine was the most effective at slowing eye growth (axial elongation), which drives myopia progression. It outperformed both 0.01% atropine and ortho-K. However, 0.04% caused more light sensitivity (photophobia), though this declined over time.
Critics of the study pointed out that subgroup sizes were small and behavior during the COVID-19 lockdowns (like time spent indoors) wasn’t accounted for, which could have skewed results. They also questioned conclusions about age-specific effectiveness due to limited data. Still, the overall finding stands: 0.01% atropine is not enough for effective myopia control, and higher doses like 0.04% may offer better results.
Comments
Post a Comment
Leave a Comment or Question: